与前叶退行相关的大脑脂质组的表征 MAPT P301S突变
Almudena Maroto-Juanes1, Thomas Vogels2, Sascha Koppes-den Hertog1
1Department of Functional Genomics, Center for Neurogenomics and Cognitive Research (CNCR), Vrije University (VU), Amsterdam, the Netherlands; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Journal of lipid research
|November 29, 2025
概括
在MAPT基因的突变导致前叶退化 (FTLD). 这项研究表明,MAPT P301S突变改变了大脑脂质代谢,随着高酸化Tau (pTau) 的积累,进一步观察到的变化.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 遗传学 是一个
背景情况:
- 微管相关蛋白tau (MAPT) 基因的突变与前叶退行症 (FTLD) 有关.
- 脂质变化与阿尔茨海默氏症等神经退行性疾病有关,但它们在原发性病症中的作用尚不清楚.
研究的目的:
- 研究FTLD相关的MAPT P301S突变对大脑脂质代谢的影响.
- 为了确定tau病理是否影响体内脂质的变化.
主要方法:
- 使用了一种具有MAPT P301S突变的tau转基因小鼠模型.
- 使用质谱法分析大脑脂质配置.
主要成果:
- 该MAPT P301S突变增加了二甲糖,六糖胺和乳糖胺,同时降低了特定的三甲糖.
- 在高酸化Tau (pTau) 积累之前,胆固醇代谢没有受到影响.
- 积累pTau与中性脂质 (胆固醇,甘油三) 的增加以及胆固醇合成和周转率的降低相关.
结论:
- 在小鼠模型中,MAPT P301S突变会诱导明显的脑脂质组变化.
- 病理进展显著影响大脑脂质代谢,影响脂质合成和积累.
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35


